17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL-DERIVATIVES,METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES

• Main Authors: ROTGERI ANDREA, BONE WILHELM, KLAR ULRICH, SCHWEDE WOLFGANG, MOLLER CARSTEN
• Format: Patent
• Language: English
• Published: 30.11.2022

17-Hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives (I) are new. 17-Hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) and their stereoisomers, salts, solvate or solvate of the salts, including all crystal modifications, are new. R 1> : Y 1>or a phenyl ring substituted by 1 or 2 Y 1>; Y 1> : SR 2>, S(O)R 3>, S(O) 2R 3>, S(O)(NH)R 3>, S(O)(NR 4>)R 3>or S(O) 2NR 9>R 10>; R 2> : H, 1-6C-alkyl, 7-10C-aralkyl or aryl; R 3> : 1-6C-alkyl or aryl; R 4> : S(O) 2R 6>; R 6> : phenyl or 4-methylphenyl; X : O, NOR 7>or NNHSO 2R 7>; either R 9>, R 10> : H, 1-10C-alkyl or aryl; or R 9>R 10>N : an optionally saturated 3-8-membered heterocyclic ring; and R 7> : H, 1-10C-alkyl or aryl. An independent claim is included for a medicament comprising (I) in combination with a further active agent and an auxiliary material. [Image] ACTIVITY : Gynecological; Cytostatic; Contraceptive. MECHANISM OF ACTION : Progesterone receptor antagonist. The progesterone receptor A antagonistic activity of (I) was tested using stable transfectant human neuroblastoma cells. The results showed that 4'-[(11beta , 17beta )-17-hydroxy-3-oxo-17-(pentafluoroethyl)estra-4,9-dien-11-yl]-N,N-dimethylbiphenyl-4-sulfonamide exhibited an IC 5 0value of 0.01 nmole/l.